Skip to main content

Prolactinoma - which patients react favorably to cabergoline medication? Cover

.blurhash-client-img { display: none !important; }

Prolactinoma - which patients react favorably to cabergoline medication?

Endocrine Regulations

Volume 56 (2022): Issue 4 (October 2022)

By: Savas Karatas, Yalcin Hacioglu and Taskin Rakicioglu

Open Access

|Oct 2022

Articles in this issue

DOI: https://doi.org/10.2478/enr-2022-0030 | Journal eISSN: 1336-0329 | Journal ISSN: 1210-0668

Journal RSS Feed

Language: English

Page range: 279 - 283

Published on: Oct 20, 2022

Published by: Slovak Academy of Sciences, Institute of Experimental Endocrinology

In partnership with: Paradigm Publishing Services

Keywords:

Related subjects:

Molecular biology,

Basic medical science,

Basic medical science, other,

Clinical medicine,

Internal medicine,

Endocrinology, diabetology

© 2022 Savas Karatas, Yalcin Hacioglu, Taskin Rakicioglu, published by Slovak Academy of Sciences, Institute of Experimental Endocrinology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 56 (2022): Issue 4 (October 2022)

Previous article